

# Rajkumar Savai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7917388/publications.pdf>

Version: 2024-02-01

167  
papers

14,718  
citations

19608

61  
h-index

19690

117  
g-index

170  
all docs

170  
docs citations

170  
times ranked

15349  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic deletion of p66shc and/or cyclophilin D results in decreased pulmonary vascular tone. <i>Cardiovascular Research</i> , 2022, 118, 305-315.	1.8	8
2	Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia. <i>European Respiratory Journal</i> , 2022, 59, 2002248.	3.1	35
3	Myeloid-cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice. <i>European Respiratory Journal</i> , 2022, 59, 2101153.	3.1	13
4	Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 546.	1.8	16
5	Picturing of the Lung Tumor Cellular Composition by Multispectral Flow Cytometry. <i>Frontiers in Immunology</i> , 2022, 13, 827719.	2.2	5
6	Disruption of Prostaglandin E2 Signaling in Cancer-Associated Fibroblasts Limits Mammary Carcinoma Growth but Promotes Metastasis. <i>Cancer Research</i> , 2022, 82, 1380-1395.	0.4	10
7	LncRNAs: Emerging Regulators of PDGF Signaling. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, , .	1.4	0
8	SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension. <i>Circulation</i> , 2022, 145, 916-933.	1.6	21
9	Phosphatidylserine Synthase PTDSS1 Shapes the Tumor Lipidome to Maintain Tumor-Promoting Inflammation. <i>Cancer Research</i> , 2022, 82, 1617-1632.	0.4	11
10	Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	15
11	Mitochondrial Respiration in Peripheral Blood Mononuclear Cells Negatively Correlates with Disease Severity in Pulmonary Arterial Hypertension. <i>Journal of Clinical Medicine</i> , 2022, 11, 4132.	1.0	7
12	Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD. <i>Cells</i> , 2022, 11, 2121.	1.8	5
13	Targeting Jak-Stat Signaling in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 100-114.	1.4	37
14	Zooming into Cellular and Molecular Heterogeneity of Pulmonary Hypertension. What More Single-Cell Omics Can Offer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 941-943.	2.5	3
15	Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. <i>British Journal of Pharmacology</i> , 2021, 178, 31-53.	2.7	18
16	Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy. <i>British Journal of Pharmacology</i> , 2021, 178, 54-71.	2.7	69
17	Therapeutic Potential of Regorafenib—A Multikinase Inhibitor in Pulmonary Hypertension. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1502.	1.8	4
18	Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience. <i>Lung Cancer</i> , 2021, 153, 150-157.	0.9	45

#	ARTICLE	IF	CITATIONS
19	Noninvasive Surrogate Markers of Pulmonary Hypertension Are Associated with Poor Survival in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1316-1319.	2.5	6
20	Depletion of Numb and Numbl like in Murine Lung Epithelial Cells Ameliorates Bleomycin-Induced Lung Fibrosis by Inhibiting the $\beta$ -Catenin Signaling Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 639162.	1.8	5
21	On the origin of germ cell neoplasia in situ: Dedifferentiation of human adult Sertoli cells in cross talk with seminoma cells in vitro. <i>Neoplasia</i> , 2021, 23, 731-742.	2.3	4
22	Exposomes to Exosomes: Exosomes as Tools to Study Epigenetic Adaptive Mechanisms in High-Altitude Humans. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8280.	1.2	3
23	Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. <i>Cancers</i> , 2021, 13, 4127.	1.7	7
24	Reply to: Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1113.	2.5	0
25	Epigenetic Regulation by <i>Suv4-20h1</i> in Cardiopulmonary Progenitor Cells Is Required to Prevent Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. <i>Circulation</i> , 2021, 144, 1042-1058.	1.6	9
26	Adenylate Kinase 4 A Key Regulator of Proliferation and Metabolic Shift in Human Pulmonary Arterial Smooth Muscle Cells via Akt and HIF-1 $\alpha$ Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10371.	1.8	11
27	Disrupted PI3K subunit p110 $\alpha$ signaling protects against pulmonary hypertension and reverses established disease in rodents. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	12
28	Small extracellular vesicle-derived miR-574-5p regulates PGE $_2$ biosynthesis via TLR7/8 in lung cancer. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12143.	5.5	21
29	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. <i>Cancers</i> , 2021, 13, 208.	1.7	10
30	Epithelial cell plasticity defines heterogeneity in lung cancer. <i>Cellular Signalling</i> , 2020, 65, 109463.	1.7	17
31	Metabolism in tumour-associated macrophages: a quid pro quo with the tumour microenvironment. <i>European Respiratory Review</i> , 2020, 29, 200134.	3.0	25
32	IRAG1 Deficient Mice Develop PKG1 $\beta$ Dependent Pulmonary Hypertension. <i>Cells</i> , 2020, 9, 2280.	1.8	7
33	Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats. <i>Pulmonary Circulation</i> , 2020, 10, 1-16.	0.8	9
34	Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. <i>Cancers</i> , 2020, 12, 3528.	1.7	13
35	Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2020, 80, 4414-4425.	0.4	109
36	Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas. <i>Cells</i> , 2020, 9, 1755.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Metastasis-Associated Protein 2 Represses NF- $\kappa$ B to Reduce Lung Tumor Growth and Inflammation. <i>Cancer Research</i> , 2020, 80, 4199-4211.	0.4	9
38	Identification of tumor-associated macrophage subsets that are associated with breast cancer prognosis. <i>Clinical and Translational Medicine</i> , 2020, 10, e239.	1.7	25
39	A FOX-like Mechanism Regulating Lung Fibroblasts: Are We Getting There?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 63, 723-724.	1.4	1
40	NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. <i>Nature Metabolism</i> , 2020, 2, 532-546.	5.1	23
41	Reprogramming of tumor-associated macrophages by targeting $\beta$ -catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. <i>Science Advances</i> , 2020, 6, eaaz6105.	4.7	110
42	Tumor-derived exosomes in the regulation of macrophage polarization. <i>Inflammation Research</i> , 2020, 69, 435-451.	1.6	153
43	Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk. <i>Frontiers in Oncology</i> , 2020, 10, 324.	1.3	76
44	Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 3560-3575.	3.9	103
45	S1PR4 ablation reduces tumor growth and improves chemotherapy via CD8+ T cell expansion. <i>Journal of Clinical Investigation</i> , 2020, 130, 5461-5476.	3.9	48
46	Hypoxia-inducible factor signaling in pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2020, 130, 5638-5651.	3.9	104
47	Cancer and pulmonary hypertension: Learning lessons and real-life interplay. <i>Global Cardiology Science &amp; Practice</i> , 2020, 2020, e202010.	0.3	1
48	Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus. <i>Frontiers in Immunology</i> , 2019, 10, 1808.	2.2	69
49	Reply to Bogaard et al.: Emphysema Is "at the Most" Only a Mild Phenotype in the Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1450-1452.	2.5	4
50	Depletion of Bone Marrow-Derived Fibrocytes Attenuates TAA-Induced Liver Fibrosis in Mice. <i>Cells</i> , 2019, 8, 1210.	1.8	12
51	Phenotypic Plasticity of Fibroblasts during Mammary Carcinoma Development. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4438.	1.8	19
52	Inactivation of nuclear histone deacetylases by EP300 disrupts the MiCEE complex in idiopathic pulmonary fibrosis. <i>Nature Communications</i> , 2019, 10, 2229.	5.8	53
53	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. <i>Nature Communications</i> , 2019, 10, 2204.	5.8	69
54	A RASSF1A-HIF1 $\alpha$ loop drives Warburg effect in cancer and pulmonary hypertension. <i>Nature Communications</i> , 2019, 10, 2130.	5.8	77

#	ARTICLE	IF	CITATIONS
55	Lamin B1 loss promotes lung cancer development and metastasis by epigenetic derepression of RET. <i>Journal of Experimental Medicine</i> , 2019, 216, 1377-1395.	4.2	45
56	miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. <i>FASEB Journal</i> , 2019, 33, 6933-6947.	0.2	30
57	Riociguat for treatment of pulmonary hypertension in COPD: a translational study. <i>European Respiratory Journal</i> , 2019, 53, 1802445.	3.1	25
58	Drug repositioning as an effective therapy for protease-activated receptor 2 inhibition. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 1522-1526.	1.2	0
59	The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. <i>Frontiers in Oncology</i> , 2019, 9, 1550.	1.3	26
60	Eplerenone attenuates pathological pulmonary vascular rather than right ventricular remodeling in pulmonary arterial hypertension. <i>BMC Pulmonary Medicine</i> , 2018, 18, 41.	0.8	46
61	ASK1 Inhibition Halts Disease Progression in Preclinical Models of Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 373-385.	2.5	78
62	FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. <i>EMBO Molecular Medicine</i> , 2018, 10, 276-293.	3.3	85
63	Phytochemicals as modulators of M1-M2 macrophages in inflammation. <i>Oncotarget</i> , 2018, 9, 17937-17950.	0.8	143
64	Polypharmacology or Promiscuity? Structural Interactions of Resveratrol With Its Bandwagon of Targets. <i>Frontiers in Pharmacology</i> , 2018, 9, 1201.	1.6	35
65	Evaluating Systolic and Diastolic Cardiac Function in Rodents Using Microscopic Computed Tomography. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007653.	1.3	10
66	<sup>3</sup> -Deoxy- <sup>3</sup> -[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007402.	1.3	14
67	Repurposing Thioridazine (TDZ) as an anti-inflammatory agent. <i>Scientific Reports</i> , 2018, 8, 12471.	1.6	22
68	Nintedanib in Severe Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 808-810.	2.5	17
69	Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2018, 128, 1720-1723.	3.9	46
70	Targeting CREB-binding protein overrides LPS induced radioresistance in non-small cell lung cancer cell lines. <i>Oncotarget</i> , 2018, 9, 28976-28988.	0.8	6
71	Amplified canonical transforming growth factor- $\beta$ signalling via heat shock protein 90 in pulmonary fibrosis. <i>European Respiratory Journal</i> , 2017, 49, 1501941.	3.1	66
72	Macrophage Regulation during Vascular Remodeling: Implications for Pulmonary Hypertension Therapy. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 56, 556-558.	1.4	18

#	ARTICLE	IF	CITATIONS
73	Epigenetic silencing of downstream genes mediated by tandem orientation in lung cancer. Scientific Reports, 2017, 7, 3896.	1.6	14
74	Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function. Circulation, 2017, 136, 65-79.	1.6	196
75	Lipoteichoic acids from Staphylococcus aureus stimulate proliferation of human non-small-cell lung cancer cells in vitro. Cancer Immunology, Immunotherapy, 2017, 66, 799-809.	2.0	33
76	Maintained right ventricular pressure overload induces ventricular arterial decoupling in mice. Experimental Physiology, 2017, 102, 180-189.	0.9	18
77	Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. Science Translational Medicine, 2017, 9, .	5.8	69
78	p38 MAPK Inhibition Improves Heart Function in Pressure-Loaded Right Ventricular Hypertrophy. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 603-614.	1.4	72
79	Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 425-437.	2.5	117
80	Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy. Oncotarget, 2017, 8, 48436-48452.	0.8	216
81	S1PR1 on tumor-associated macrophages promotes lymphangiogenesis and metastasis via NLRP3/IL-1 $\beta$ . Journal of Experimental Medicine, 2017, 214, 2695-2713.	4.2	216
82	Abstract 944: Chemokine receptor signaling as a new tool to improve lung cancer diagnostics and therapy., 2017, , .		0
83	Abstract 1140: Characterization of a novel PDE10 inhibitor in lung tumor cells and an orthotopic mouse model of lung cancer. , 2017, , .		0
84	Proangiogenic and wound healing molecular and histological fingerprint of chronic thromboembolic pulmonary hypertension. , 2017, , .		0
85	LSC - 2017 - Reprogramming Of Tumor Associated Macrophages By Modulating Wnt/ $\beta$ -catenin Signalling In Lung Cancer. , 2017, , .		0
86	Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate. , 2017, , .		0
87	Histone Deacetylase 7 regulates master transcription factors and modulates mitochondrial function. , 2017, , .		0
88	Non-invasive lung cancer diagnosis by detection of GATA6 and NKX2-1 isoforms in exhaled breath condensate. EMBO Molecular Medicine, 2016, 8, 1380-1389.	3.3	29
89	The emerging role of epigenetics in pulmonary hypertension. European Respiratory Journal, 2016, 48, 903-917.	3.1	32
90	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. European Respiratory Journal, 2016, 48, 1137-1149.	3.1	89

#	ARTICLE	IF	CITATIONS
91	miR-223â€™IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. <i>Cardiovascular Research</i> , 2016, 111, 184-193.	1.8	54
92	Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 47-57.	1.4	59
93	CRISPR-Cas9â€™based target validation for p53-reactivating model compounds. <i>Nature Chemical Biology</i> , 2016, 12, 22-28.	3.9	74
94	Abstract 1594: Contribution of Stromal Lymphocytes to Lung Cancer Metastasis: Role in Epithelial Mesenchymal Transition. , 2016, , .		1
95	RASSF1A regulates ROS-HIF axis in hypoxia driven pulmonary hypertension. , 2016, , .		0
96	LSC Abstract â€™ Histone deacetylase 7 mediated metabolic remodeling: A new crosslink between pulmonary hypertension and cancer. , 2016, , .		0
97	Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. <i>PLoS ONE</i> , 2015, 10, e0139073.	1.1	101
98	Macrophage and Cancer Cell Cross-talk via CCR2 and CX3CR1 Is a Fundamental Mechanism Driving Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 437-447.	2.5	186
99	Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. <i>Thorax</i> , 2015, 70, 1022-1032.	2.7	106
100	Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice. <i>PLoS ONE</i> , 2015, 10, e0129327.	1.1	29
101	Sequential Salinomycin Treatment Results in Resistance Formation through Clonal Selection of Epithelial-Like Tumor Cells. <i>Translational Oncology</i> , 2014, 7, 702-711.	1.7	10
102	Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferation and inflammatory mediator synthesis. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1297-1306.	2.0	58
103	Histological Characterization of Mast Cell Chymase in Patients with Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. <i>Pulmonary Circulation</i> , 2014, 4, 128-136.	0.8	36
104	Stimulation of Soluble Guanylate Cyclase Prevents Cigarette Smokeâ€™induced Pulmonary Hypertension and Emphysema. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 1359-1373.	2.5	80
105	Adventitial Fibroblasts Induce a Distinct Proinflammatory/Profibrotic Macrophage Phenotype in Pulmonary Hypertension. <i>Journal of Immunology</i> , 2014, 193, 597-609.	0.4	162
106	Elimination of B-RAF in Oncogenic C-RAF-expressing Alveolar Epithelial Type II Cells Reduces MAPK Signal Intensity and Lung Tumor Growth. <i>Journal of Biological Chemistry</i> , 2014, 289, 26804-26816.	1.6	9
107	Impact of S-Adenosylmethionine Decarboxylase 1 on Pulmonary Vascular Remodeling. <i>Circulation</i> , 2014, 129, 1510-1523.	1.6	23
108	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. <i>Nature Medicine</i> , 2014, 20, 1289-1300.	15.2	233

#	ARTICLE	IF	CITATIONS
109	Novel and Emerging Therapies for Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 394-400.	2.5	75
110	ABCB4 is frequently epigenetically silenced in human cancers and inhibits tumor growth. Scientific Reports, 2014, 4, 6899.	1.6	24
111	Mitochondrial Hyperpolarization in Pulmonary Vascular Remodeling. Mitochondrial Uncoupling Protein Deficiency as Disease Model. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 358-367.	1.4	66
112	Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy. Cancer Immunology, Immunotherapy, 2013, 62, 1283-1292.	2.0	19
113	Endotoxin induces proliferation of NSCLC in vitro and in vivo: role of COX-2 and EGFR activation. Cancer Immunology, Immunotherapy, 2013, 62, 309-320.	2.0	45
114	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. International Journal of Cardiology, 2013, 167, 2630-2637.	0.8	35
115	Function of NADPH Oxidase 1 in Pulmonary Arterial Smooth Muscle Cells After Monocrotaline-Induced Pulmonary Vascular Remodeling. Antioxidants and Redox Signaling, 2013, 19, 2213-2231.	2.5	62
116	Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension. Circulation, 2013, 127, 1128-1138.	1.6	482
117	Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene, 2013, 32, 1121-1134.	2.6	120
118	Heterogeneity in Lung <sup>18</sup> F FDG Uptake in Pulmonary Arterial Hypertension. Circulation, 2013, 128, 1214-1224.	1.6	107
119	Differential Effects of Drugs Targeting Cancer Stem Cell (CSC) and Non-CSC Populations on Lung Primary Tumors and Metastasis. PLoS ONE, 2013, 8, e79798.	1.1	75
120	Abstract 2604: Involvement of circulating fibrocytes in the progression of adenocarcinomas by modulating EMT and tumor microenvironment.. , 2013, , .		0
121	Abstract 4681: Characterization of pulmonary hypertension in lung cancer.. , 2013, , .		0
122	Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 1354-1365.	1.1	108
123	Inhibition of MicroRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 409-419.	2.5	206
124	Zyxin Is a Transforming Growth Factor- $\beta$ (TGF- $\beta$ )/Smad3 Target Gene That Regulates Lung Cancer Cell Motility via Integrin $\alpha$ 5 $\beta$ 1. Journal of Biological Chemistry, 2012, 287, 31393-31405.	1.6	61
125	Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 897-908.	2.5	296
126	E-cadherin Controls Bronchiolar Progenitor Cells and Onset of Preneoplastic Lesions in Mice. Neoplasia, 2012, 14, 1164-1171.	2.3	24



#	ARTICLE	IF	CITATIONS
127	The Soluble Guanylate Cyclase Stimulator Riociguat Ameliorates Pulmonary Hypertension Induced by Hypoxia and SU5416 in Rats. PLoS ONE, 2012, 7, e43433.	1.1	100
128	Tumor-stromal interactions in lung cancer: novel candidate targets for therapeutic intervention. Expert Opinion on Investigational Drugs, 2012, 21, 1107-1122.	1.9	30
129	Mechanisms of disease: pulmonary arterial hypertension. Nature Reviews Cardiology, 2011, 8, 443-455.	6.1	605
130	Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2011, 20, 61-74.	1.9	9
131	Inducible NOS Inhibition Reverses Tobacco-Smoke-Induced Emphysema and Pulmonary Hypertension in Mice. Cell, 2011, 147, 293-305.	13.5	293
132	Expression of B-RAF V600E in Type II Pneumocytes Causes Abnormalities in Alveolar Formation, Airspace Enlargement and Tumor Formation in Mice. PLoS ONE, 2011, 6, e29093.	1.1	3
133	cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases. Circulation, 2011, 123, 1194-1204.	1.6	42
134	The Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis. Science Translational Medicine, 2011, 03, 87ra53.	5.8	59
135	Targeting non-malignant disorders with tyrosine kinase inhibitors. Nature Reviews Drug Discovery, 2010, 9, 956-970.	21.5	118
136	Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 158-167.	2.5	118
137	Imatinib in Pulmonary Arterial Hypertension Patients with Inadequate Response to Established Therapy. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1171-1177.	2.5	331
138	Inhibition of Urokinase Activity Reduces Primary Tumor Growth and Metastasis Formation in a Murine Lung Carcinoma Model. American Journal of Respiratory and Critical Care Medicine, 2010, 181, 611-619.	2.5	46
139	PDGF Receptor and its Antagonists: Role in Treatment of PAH. Advances in Experimental Medicine and Biology, 2010, 661, 435-446.	0.8	55
140	Targeting cancer with phosphodiesterase inhibitors. Expert Opinion on Investigational Drugs, 2010, 19, 117-131.	1.9	123
141	Expression and Activity of Phosphodiesterase Isoforms during Epithelial Mesenchymal Transition: The Role of Phosphodiesterase 4. Molecular Biology of the Cell, 2009, 20, 4751-4765.	0.9	84
142	The Noncanonical WNT Pathway Is Operative in Idiopathic Pulmonary Arterial Hypertension. American Journal of Respiratory Cell and Molecular Biology, 2009, 40, 683-691.	1.4	93
143	Amplification of Lipopolysaccharide-Induced Cytokine Synthesis in Non-Small Cell Lung Cancer/Neutrophil Cocultures. Molecular Cancer Research, 2009, 7, 1729-1735.	1.5	12
144	Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. Journal of the American College of Cardiology, 2009, 54, S10-S19.	1.2	605

#	ARTICLE	IF	CITATIONS
145	Future Perspectives for the Treatment of Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , 2009, 54, S108-S117.	1.2	62
146	Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer. <i>Neoplasia</i> , 2009, 11, 48-56.	2.3	87
147	Direct eicosanoid profiling of the hypoxic lung by comprehensive analysis via capillary liquid chromatography with dual online photodiode-array and tandem mass-spectrometric detection. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 390, 697-714.	1.9	23
148	Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. <i>Circulation</i> , 2008, 118, 2081-2090.	1.6	139
149	Spatiotemporal Expression of flk-1 in Pulmonary Epithelial Cells during Lung Development. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2008, 39, 163-170.	1.4	14
150	Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 188-196.	2.5	82
151	A Combination Hybrid-Based Vaccination/Adoptive Cellular Therapy to Prevent Tumor Growth by Involvement of T Cells. <i>Cancer Research</i> , 2007, 67, 5443-5453.	0.4	26
152	Non-invasive screening of lung nodules in mice comparing a novel volumetric computed tomography with a clinical multislice CT. <i>Oncology Reports</i> , 2007, 17, 707-12.	1.2	8
153	Increased Protein Arginine Methylation in Chronic Hypoxia. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2006, 35, 436-443.	1.4	78
154	Impact of HIF $\alpha$ 1 $\pm$ and HIF $\alpha$ 2 $\pm$ on proliferation and migration of human pulmonary artery fibroblasts in hypoxia. <i>FASEB Journal</i> , 2006, 20, 163-165.	0.2	52
155	Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19093-19098.	3.3	273
156	Role of Hypoxia-Inducible Factor-1 $\pm$ in Hypoxia-Induced Apoptosis of Primary Alveolar Epithelial Type II Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2005, 32, 395-403.	1.4	87
157	Hypoxia-driven proliferation of human pulmonary artery fibroblasts: cross-talk between HIF $\alpha$ 1 $\pm$ and an autocrine angiotensin system. <i>FASEB Journal</i> , 2005, 19, 1-26.	0.2	72
158	Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2005, 353, 2148-2157.	13.9	2,237
159	Potential Applications of Flat-Panel Volumetric CT in Morphologic, Functional Small Animal Imaging. <i>Neoplasia</i> , 2005, 7, 730-740.	2.3	63
160	Analysis of Tumor Vessel Supply in Lewis Lung Carcinoma in Mice by Fluorescent Microsphere Distribution and Imaging with Micro- and Flat-Panel Computed Tomography. <i>American Journal of Pathology</i> , 2005, 167, 937-946.	1.9	32
161	Imatinib for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , 2005, 353, 1412-1413.	13.9	440
162	Reversal of experimental pulmonary hypertension by PDGF inhibition. <i>Journal of Clinical Investigation</i> , 2005, 115, 2811-2821.	3.9	917

#	ARTICLE	IF	CITATIONS
163	Upregulation of NAD(P)H oxidase 1 in hypoxia activates hypoxia-inducible factor 1 via increase in reactive oxygen species. <i>Free Radical Biology and Medicine</i> , 2004, 36, 1279-1288.	1.3	183
164	RNA interference for HIF-1 $\alpha$ inhibits its downstream signalling and affects cellular proliferation. <i>Biochemical and Biophysical Research Communications</i> , 2003, 312, 571-577.	1.0	68
165	cDNA Array Hybridization after Laser-Assisted Microdissection from Nonneoplastic Tissue. <i>American Journal of Pathology</i> , 2002, 160, 81-90.	1.9	75
166	Cell Density Regulates Neutrophil IL-8 Synthesis: Role of IL-1 Receptor Antagonist and Soluble TNF Receptors. <i>Journal of Immunology</i> , 2001, 166, 6287-6293.	0.4	30
167	Real-time quantitative RT-PCR after laser-assisted cell picking. <i>Nature Medicine</i> , 1998, 4, 1329-1333.	15.2	547